We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa (CogUK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01367236
Recruitment Status : Completed
First Posted : June 7, 2011
Last Update Posted : January 10, 2017
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:

The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period.

The study will compare anti-HIV therapy combinations which are currently in use.

The patients will not have had any previous treatment for their HIV infection.


Condition or disease Intervention/treatment Phase
HIV Impaired Cognition Drug: standard care Drug: novel treatment Phase 4

Detailed Description:

Impairment in neurocognitive(NC) function in HIV-infected subjects in the current anti-retroviraltreatment (cART) era has been associated with poor compliance with cART, reduced quality-of-life and increased mortality. Reported factors associated with the development of NC function impairment in HIV disease and risks associated with progression of such impairment include degree of immune suppression related to HIV infection, other chronic viral infections (such as chronic hepatitis C co-infection), age and central nervous system (CNS) antiretroviral drug exposure.

One modifiable factor which may be associated with the evolution of NC function impairment is the direct effect of cART on the central-nervous-system (CNS). Certain antiretroviral drugs such as zidovudine, lamivudine, abacavir, nevirapine, efavirenz and indinavir are known to achieve optimal exposure in the cerebro-spinal-fluid (CSF) whereas other drugs, such as the majority of the HIV-1 protease inhibitors penetrate less effectively. Studies to date suggest different cART regimens may have differing effects on NC performance. In the EuroSIDA study, the use of nucleoside-reverse-transcriptase inhibitors was found to specifically protect against the development of HIV related brain disease. More recently, in a small prospective study, ALTAIR, different effect on cerebral function was reported in subjects randomised to commence three different cART regimens.

The investigators propose, in a prospective, randomised study to assess the effects of two different antiretroviral regimens on NC function in HIV infected subjects commencing antiretroviral therapy for the first time.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised, Prospective Study, Assessing Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa.
Study Start Date : January 2013
Primary Completion Date : October 2015
Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: standard care

treatment with:

  • atazanavir 300 mg daily
  • ritonavir 100 mg daily
  • tenofovir 245 mg daily*
  • emtricitabine 200 mg daily* * as the fixed dose combination Truvada™
Drug: standard care
  • atazanavir 300 mg daily
  • ritonavir 100 mg daily
  • tenofovir 245 mg daily*
  • emtricitabine 200 mg daily*
Active Comparator: Novel therapeutic approach
  • darunavir 800 mg daily
  • ritonavir 100 mg daily
  • lamivudine 300 mg daily**
  • abacavir 600 mg daily**
  • maraviroc 150 mg once daily ** as the fixed dose combination Kivexa ™
Drug: novel treatment
  • darunavir 800 mg daily
  • ritonavir 100 mg daily
  • lamivudine 300 mg daily** and abacavir 600mgs daily**
  • maraviroc 150 mg once daily


Outcome Measures

Primary Outcome Measures :
  1. cognitive function [ Time Frame: 48 weeks ]

    When commencing antiretroviral therapy (anti-HIV therapy) for the first time, improvements in the function of the brain are frequently observed. For example memory and concentration may improve. However, whether these improvements may differ between different anti-HIV therapies is largely unknown.

    The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period.



Secondary Outcome Measures :
  1. brain function [ Time Frame: 48 weeks ]
    The study team will assess the brain functions at each visit. Also the blood will be monitored for efficacy of treatment in the two study limbs at all visits (this is part of normal care). Likewise the results of the MRI scans will be compared. The lumbar puncture performed at the final visit will obtain samples of CSF and certain test will be performed on this to examine the differences between the two study treatments. The comparison of the scan and lumbar puncture results will indicate how the brain is differently effected with different treatments.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV-1 infected males or females
  • signed informed consent
  • no previous antiretroviral treatment since HIV diagnosis
  • screening CD4+ lymphocyte count <= 350 cells/ųL
  • susceptible to all currently licensed (Nucleoside Reverse Transcriptase Inhibitors) NRTIs, (Non-Nucleoside Reverse Transcriptase Inhibitors) NNRTIs and PIs based on HIV-1 genotypic resistance report
  • CCR5-tropic HIV based on genotypic resistance testing*

Exclusion Criteria:

  • • existing neurological disease

    • hepatitis B or hepatitis C co-infection
    • age under 18 years
    • screening laboratory parameters > grade 2 (with the exception of cholesterol and triglycerides)
    • current history of major depression or psychosis
    • recent head injury (past three months)
    • current alcohol abuse or drug dependence
    • active opportunistic infection or significant co-morbidities
    • patients who are receiving other concomitant medication which are not permitted, as listed in appendix 2
    • female patients of child-bearing potential who:

      • have a positive serum pregnancy test at screening or during the study
      • are breast feeding
      • are planning to become pregnant
    • all participants unwilling to use a barrier method of contraception
    • patients who in the opinion of the investigator are not candidates for inclusion in the study
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01367236


Locations
United Kingdom
Birmingham Heartlands Hospital:
Birmingham, United Kingdom
Brighton and Sussex University Hospital NHS Trust:
Brighton, United Kingdom, BN1 9RE
St. Mary's Hospital
London:, United Kingdom, W2 1NY
Kings College Hospital
London, United Kingdom, SE5 9RJ
Chelsea and Westminster Hospital NHS Trust
London, United Kingdom, SW10 9NH
St. Thomas' Hospital
London, United Kingdom
Sponsors and Collaborators
Imperial College London
Pfizer
More Information

Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01367236     History of Changes
Other Study ID Numbers: 1733
2011-002656-14 ( EudraCT Number )
First Posted: June 7, 2011    Key Record Dates
Last Update Posted: January 10, 2017
Last Verified: December 2016

Additional relevant MeSH terms:
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Ritonavir
Darunavir
Atazanavir Sulfate
Maraviroc
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
CCR5 Receptor Antagonists
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors